Immune Systems Advisor

The nation's hospitals are overcrowded — not just busy, but full. According to the Centers for Disease Control and Prevention (CDC), the 2024–25 flu season is the worst the United States has seen in over 15 years. It’s not just one city facing the crisis; New York, Houston, and Phoenix have reported the worst flu numbers since the severe 2017–18 season. So far, there have been more than 47 million flu-related illnesses nationwide, resulting in over 610,000 hospitalizations and more than 26,000 fatalities. The season has become particularly deadly for the elderly population, marking the deadliest flu season for this group since 2010. And there is still about a month and a half left in the flu season to come. What is Going On? The culprit is not a new or mystery virus but rather influenza itself, which this season is striking quicker, dispersing more widely, and causing severe illness across demographics, including children and healthy adults. The hospitalization rate for the 2024–25...

As of September 2025, Long COVID—also known as post-COVID-19 condition—continues to affect millions worldwide, with symptoms ranging from fatigue and brain fog to cardiovascular issues and respiratory problems that persist for months or years after the initial SARS-CoV-2 infection. While no FDA-approved treatments specifically for Long COVID exist yet, significant progress has been made in 2025 through research initiatives like the NIH's RECOVER program, which has completed enrollment for several observational studies and is actively testing interventions in clinical trials. This article reviews emerging treatments, with a focus on those targeting the SARS-CoV-2 spike protein—a key suspect in viral persistence and ongoing symptoms—and broader approaches addressing inflammation, immune dysregulation, and symptom management. Data from recent studies, including preclinical models and human trials, highlight promising avenues, though many remain investigational. Understanding the Role ...

Currently, there are no published simulated clinical trials (e.g., in silico clinical trial models or virtual patient cohort studies) specifically evaluating the combination of nattokinase, curcumin, bromelain, and ivermectin for Long COVID or spike protein syndrome. However, in silico studies, in vitro research, and observational data provide a foundation for designing such a trial. Below, we outline a hypothetical framework for a simulated clinical trial based on existing evidence, proposed mechanisms, and computational modeling approaches. This framework incorporates insights from in silico and preliminary studies, addresses gaps, and aligns with the query's focus on Long COVID and spike protein-related syndromes. Simulated (In Silico) Clinical Trial Design Objective: To evaluate the efficacy and safety of a combination regimen of nattokinase, curcumin, bromelain, and ivermectin in reducing symptoms of Long COVID or spike protein syndrome (e.g., fatigue, brain fog, cardiovascula...

As we navigate the ongoing challenges of COVID-19 in September 2025, artificial intelligence (AI) has emerged as a powerful tool for predicting disease trends, outbreaks, and surges. With biannual peaks continuing to strain healthcare systems, AI-driven models help public health officials anticipate hospitalizations, variant dominance, and resource needs. This article explores how AI is transforming COVID-19 forecasting, key models in use, recent 2025 advancements, and what lies ahead. By leveraging data from sources like the CDC and WHO, these models provide actionable insights to mitigate impacts on vulnerable populations. The Role of AI in COVID-19 Forecasting AI enhances traditional epidemiological methods by processing vast datasets—including case numbers, mobility patterns, genomic sequences, and wastewater surveillance—to predict trends with greater accuracy. Unlike static models, AI systems learn from real-time data, adapting to variables like vaccination rates, human behavior...